News coverage about Depomed (NASDAQ:DEPO) has been trending somewhat positive recently, according to Alpha One Sentiment Analysis. The research firm, a subsidiary of Accern, ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Depomed earned a media sentiment score of 0.22 on Alpha One’s scale. Alpha One also assigned press coverage about the specialty pharmaceutical company an impact score of 56 out of 100, meaning that recent press coverage is somewhat likely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected AlphaOne Sentiment Analysis’s rankings:
- -$0.41 EPS Expected for Depomed Inc (DEPO) This Quarter (americanbankingnews.com)
- Depomed INC (DEPO) Holder Starboard Value LP Decreased Stake by $13.41 Million (ismboard.com)
- Pain Management Therapeutics Market Research Report: Development Insight and Manufacturers Challenge Competitors (sbwire.com)
- Shares of DEPO Down 54.0% Since Downtrend Call on Shares (mysmartrend.com)
- Depomed, Inc. (NasdaqGS:DEPO) Investor Update & Valuation Review – Ozark Times (ozarktimes.com)
A number of analysts have weighed in on the stock. Royal Bank of Canada set a $22.00 price target on shares of Depomed and gave the company a “hold” rating in a report on Saturday, March 25th. Roth Capital set a $24.00 price target on shares of Depomed and gave the company a “buy” rating in a report on Saturday, February 18th. Cantor Fitzgerald reissued a “hold” rating and issued a $19.00 price target on shares of Depomed in a report on Wednesday, March 29th. Mizuho downgraded shares of Depomed from a “buy” rating to a “neutral” rating and reduced their price target for the company from $24.00 to $17.00 in a report on Tuesday, February 14th. Finally, ValuEngine raised shares of Depomed from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Depomed presently has a consensus rating of “Hold” and an average price target of $16.83.
Shares of Depomed (DEPO) traded down 5.24% during trading on Friday, reaching $9.94. 2,068,753 shares of the company traded hands. The stock’s market capitalization is $619.67 million. Depomed has a 12 month low of $9.50 and a 12 month high of $27.02. The company has a 50-day moving average of $10.94 and a 200-day moving average of $15.35.
Depomed (NASDAQ:DEPO) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.18. Depomed had a negative return on equity of 7.49% and a negative net margin of 16.93%. The firm had revenue of $95 million for the quarter, compared to the consensus estimate of $99.48 million. During the same period in the prior year, the company earned $0.04 EPS. The company’s revenue for the quarter was down 9.2% compared to the same quarter last year. Analysts forecast that Depomed will post $0.62 earnings per share for the current fiscal year.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc and related companies with MarketBeat.com's FREE daily email newsletter.